NCT05200741

To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2

A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as Booster Vaccine for COVID-19 in Healthy Adults Who Have Received 2 Doses of BNT162b2

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: The University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety and immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as booster vaccine for COVID-19 in healthy adults who have received 2 doses of BNT162b2

Detailed description

This is a randomized, double-blinded, placebo-controlled study to evaluate the safety and immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as booster vaccine for COVID-19 in healthy adults who have received 2 doses of BNT162b2. Each subject will receive 2 vaccinations or matching placebo 3 weeks apart.

Conditions

• Covid19

Interventions

Type	Name	Description
BIOLOGICAL	DelNS1-2019-nCoV-RBD-OPT1	Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
BIOLOGICAL	Matching placebo	Solution for Intranasal Spray

Timeline

• Start date: 2022-02-08
• Primary completion: 2024-02-01
• Completion: 2024-02-01
• First posted: 2022-01-21
• Last updated: 2022-10-28

Locations

1 site across 1 country: Hong Kong